RPS6KA1 and breast carcinoma: In addition to questions posed by the current data, such as a better understanding of the disparate effects of the PCAIs on AKT phosphorylation in the two cell lines and the identification of the specific p90RSK that is phosphorylated in response to the PCAIs, future work will also involve the identification of the direct pharmacological target and evaluation of the agents in tumor-derived organoids and in an in vivo model of breast cancer.